MXPA04008932A - Parecoxib sodico cristalino. - Google Patents

Parecoxib sodico cristalino.

Info

Publication number
MXPA04008932A
MXPA04008932A MXPA04008932A MXPA04008932A MXPA04008932A MX PA04008932 A MXPA04008932 A MX PA04008932A MX PA04008932 A MXPA04008932 A MX PA04008932A MX PA04008932 A MXPA04008932 A MX PA04008932A MX PA04008932 A MXPA04008932 A MX PA04008932A
Authority
MX
Mexico
Prior art keywords
parecoxib sodium
parecoxib
sodium
accordance
pharmaceutical substance
Prior art date
Application number
MXPA04008932A
Other languages
English (en)
Spanish (es)
Inventor
Leonard J Ferro
Original Assignee
Pharmacia Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacia Corp filed Critical Pharmacia Corp
Publication of MXPA04008932A publication Critical patent/MXPA04008932A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D457/00—Heterocyclic compounds containing indolo [4, 3-f, g] quinoline ring systems, e.g. derivatives of ergoline, of the formula:, e.g. lysergic acid
    • C07D457/04—Heterocyclic compounds containing indolo [4, 3-f, g] quinoline ring systems, e.g. derivatives of ergoline, of the formula:, e.g. lysergic acid with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 8
    • C07D457/06—Lysergic acid amides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
    • C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
    • C07D261/08—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Medicinal Preparation (AREA)
MXPA04008932A 2002-03-15 2003-03-12 Parecoxib sodico cristalino. MXPA04008932A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US36456702P 2002-03-15 2002-03-15
US41798702P 2002-10-11 2002-10-11
PCT/US2003/007484 WO2003078408A1 (en) 2002-03-15 2003-03-12 Crystalline parecoxib sodium

Publications (1)

Publication Number Publication Date
MXPA04008932A true MXPA04008932A (es) 2004-11-26

Family

ID=28045416

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA04008932A MXPA04008932A (es) 2002-03-15 2003-03-12 Parecoxib sodico cristalino.

Country Status (18)

Country Link
US (1) US20030232871A1 (enExample)
EP (1) EP1485362A1 (enExample)
JP (1) JP2005529084A (enExample)
KR (1) KR100763045B1 (enExample)
CN (1) CN1642926A (enExample)
AR (1) AR038985A1 (enExample)
AU (1) AU2003220180A1 (enExample)
BR (1) BR0308431A (enExample)
CA (1) CA2478500A1 (enExample)
CO (1) CO5631437A2 (enExample)
IL (1) IL163780A0 (enExample)
MX (1) MXPA04008932A (enExample)
MY (1) MY148518A (enExample)
NZ (1) NZ535951A (enExample)
PL (1) PL372880A1 (enExample)
RU (1) RU2300529C2 (enExample)
TW (1) TW200400949A (enExample)
WO (1) WO2003078408A1 (enExample)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004087682A1 (en) * 2003-04-04 2004-10-14 Hetero Drugs Limited Novel crystalline forms of parecoxib sodium
CA2540895C (en) 2003-10-02 2016-08-02 Elan Pharmaceuticals, Inc. Combinations of ziconotide and opioids for reducing pain
CA2551523A1 (en) * 2003-12-24 2005-07-21 Pharmacia Corporation Metal salts of parecoxib as prodrugs of the cox-2 inhibitor valdecoxib for the treatment of inflammation, pain and/or fever
ITMI20040019A1 (it) * 2004-01-12 2004-04-12 Univ Bari Derivati isossazolici e loro impiego come inibitori della ciclossigenasi
US7796785B2 (en) * 2005-03-03 2010-09-14 Fujifilm Corporation Image extracting apparatus, image extracting method, and image extracting program
US20080108664A1 (en) 2005-12-23 2008-05-08 Liu Belle B Solid-state form of AMG 706 and pharmaceutical compositions thereof
US7989450B2 (en) 2008-01-11 2011-08-02 Universita' Degli Studi Di Bari Functionalized diarylisoxazoles inhibitors of ciclooxygenase
GB0919757D0 (en) * 2009-11-12 2009-12-30 Johnson Matthey Plc Polymorphs of bromfenac sodium and methods for preparing bromfenac sodium polymorphs
US8299295B2 (en) * 2009-10-15 2012-10-30 Johnson Matthey Public Limited Company Polymorphs of bromfenac sodium and methods for preparing bromfenac sodium polymorphs
CN105726496B (zh) * 2014-12-12 2019-05-28 湖南科伦药物研究有限公司 一种帕瑞昔布钠冻干粉剂、其制备方法及其粉剂产品
CN105125506A (zh) * 2015-08-18 2015-12-09 上海秀新臣邦医药科技有限公司 一种注射用帕瑞昔布钠及其制备方法
CN106580893A (zh) * 2016-12-26 2017-04-26 上药东英(江苏)药业有限公司 一种帕瑞昔布钠冻干粉针制剂
CN106692079A (zh) * 2016-12-26 2017-05-24 上药东英(江苏)药业有限公司 一种帕瑞昔布钠长效冻干粉针制剂
CN117003769B (zh) * 2023-07-11 2024-11-22 中国科学院宁波材料技术与工程研究所 氯诺昔康复合物、氯诺昔康-小檗碱共晶及其制备方法和应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GEP20032998B (en) * 1996-04-12 2003-06-25 Searle & Co Substituted Benzenesulfonamide Derivatives as Prodrugs of Cox-2 Inhibitors
ATE271385T1 (de) * 1996-10-15 2004-08-15 Searle Llc Verwendung von cyclooxygenase-2 inhibitoren zur behandlung und verbeugung von neoplasia
PE20021017A1 (es) * 2001-04-03 2002-11-24 Pharmacia Corp Composicion parenteral reconstituible
US20030105334A1 (en) * 2001-10-02 2003-06-05 Letendre Leo J. Method for preparing benzenesulfonyl compounds

Also Published As

Publication number Publication date
IL163780A0 (en) 2005-12-18
TW200400949A (en) 2004-01-16
MY148518A (en) 2013-04-30
KR20040095288A (ko) 2004-11-12
KR100763045B1 (ko) 2007-10-04
JP2005529084A (ja) 2005-09-29
CA2478500A1 (en) 2003-09-25
NZ535951A (en) 2006-02-24
CN1642926A (zh) 2005-07-20
RU2300529C2 (ru) 2007-06-10
RU2004127585A (ru) 2005-04-10
PL372880A1 (en) 2005-08-08
US20030232871A1 (en) 2003-12-18
AR038985A1 (es) 2005-02-02
EP1485362A1 (en) 2004-12-15
AU2003220180A1 (en) 2003-09-29
CO5631437A2 (es) 2006-04-28
BR0308431A (pt) 2005-01-18
WO2003078408A1 (en) 2003-09-25

Similar Documents

Publication Publication Date Title
RU2300529C2 (ru) Кристаллическая натриевая соль парекоксиба
JP7293407B2 (ja) アピキサバンおよびカルボン酸によって形成される共結晶、および、その調製法
SK287754B6 (sk) Farmaceutický prípravok, injekčný roztok a liekovka obsahujúce parekoxib alebo jeho soľ a spôsob prípravy rekonštituovateľnej selektívnej COX-2 inhibičnej kompozície
CN109111438B (zh) 用于ido抑制剂的脒类化合物
CN116925087A (zh) 一类二芳基四甘脲羧酸盐及其用途
US20030100595A1 (en) Oral dosage form of a sulfonamide prodrug
WO2016145622A1 (zh) 苯并咪唑衍生物及其制备方法和医药用途
JP2025502842A5 (enExample)
US20040092566A1 (en) Celecoxib prodrug
TWI411435B (zh) 4-環丙基甲氧基-n-(3,5-二氯-1-氧離子基吡啶-4-基)-5-(甲氧基)吡啶-2-甲醯胺於治療脊髓創傷之用途
ZA200406788B (en) Crystalline parecoxib sodium
HK1075049A (en) Crystalline parecoxib sodium
HK1106529A (en) Crystalline parecoxib sodium
CN111315746B (zh) 色氨酸羟化酶抑制剂和包括该抑制剂的药物组合物
HK1106528A (en) Crystalline parecoxib sodium
CA2405741A1 (en) Sodium salt of an azo derivative of 5-aminosalicylic acid
HK40102141A (en) A crystalline potassium salt of 1-ethyl- n -((1,2,3,5,6,7-hexahydro- s -indacen-4-yl)carbamoyl)piperidine-4 -sulfonamide
JPS5890587A (ja) イセチオン酸塩
AU2004213180B2 (en) Nitrate esters of phenylaminothiophenacetic acid derivatives
HK1081546A (zh) 塞來考昔的前藥
AU2002352646A1 (en) Oral dosage form of a sulfonamide prodrug such as parecoxib
HK40104962A (en) Salts of a pi3kdelta inhibitor, crystalline forms, methods of preparation, and uses therefore